肺腺癌；易瑞沙；毒副反应；治疗结果。
Lung neoplasm; Iressa; Toxicity reaction; Treatment outcome.
间质性肺疾病已观察到异常的患者易瑞沙。
Interstitial lung disease has been observed in patients with abnormal suggested that it should.
建议的每日剂量易瑞沙是250毫克片剂或无食物。
The recommended daily dose of IRESSA is one 250 mg tablet with or without food.
对于适用化疗的患者您是否会考虑使用易瑞沙？为什么？
Would you consider using IRESSA in patients who otherwise be suitable for chemotherapy? Why?
现在假设您需要向您的同事阐述关于易瑞沙的一些信息。
I would like you to imagine that you are presenting information about IRESSA to your peers.
医生，刚才您所阅读的简介其实就是(吉非替尼)易瑞沙。
Doctor, the profile that you just read is actually for (gefitinib) IRESSA.
您会如何使用易瑞沙？会用于几线治疗？用于哪些患者？为什么？
How would you use IRESSA? For which lines of therapy and for which patients? Why?
如果间质性肺疾病得到证实，易瑞沙应该停止，病人适当处理。
If interstitial lung disease is confirmed, it is suggested that it should stop, the patient should be appropriate treatment.
建议剂量的易瑞沙是250毫克片剂每天一次，采取带或不带食物。
Suggest dose is 250 mg tablets suggested that it should take every time, with or without food.
易瑞沙不推荐用于儿童或青少年的安全性和有效性在这些病人还没有研究。
It is suggested that it should not recommended for children or teenagers in the safety and effectiveness of these patients had not been investigated.
因此，定期肝功能测试是易瑞沙建议应慎重使用中存在的轻度至中度增加肝转氨酶。
Therefore, the liver function tests are regularly suggested that it should be careful use of suggestion of mild to moderate increase liver transaminase.
根据您刚才读的内容，您对于晚期NSCLC患者使用易瑞沙作为一线治疗的意愿有多大？
Based on what you read, how likely would you be to use IRESSA as 1st line treatment in advanced NSCLC in your patients?
研究i是易瑞沙泛亚研究的内容，研究II是根据最近针对亚裔患者所做研究的综合分析。
Study I is referring to the IPASS study while study II is a meta-analysis recently conducted using the data from all patients and those of Asian origin.
现在知道这个产品就是易瑞沙，您有什么感觉？这些信息是否影响了您对该产品的认知？为什么？怎样影响？
Now knowing that this product is referring to IRESSA, how do you feel? Does this information change your perception of the product? Why and how so?
在此次访问的最后部分我想请各位阐述以下如何才能最好的传达一幅引人注目的画面，说明易瑞沙是针对EGFR突变阳性的晚期NSCLC患者的一线治疗方法。
I would now like to focus for the remainder of our discussion on how best to convey a compelling picture for Iressa in advanced NSCLC as 1st line in EGFR mutation positive patients.
在此次访问的最后部分我想请各位阐述以下如何才能最好的传达一幅引人注目的画面，说明易瑞沙是针对EGFR突变阳性的晚期NSCLC患者的一线治疗方法。
I would now like to focus for the remainder of our discussion on how best to convey a compelling picture for Iressa in advanced NSCLC as 1st line in EGFR mutation positive patients.
应用推荐